Lung, Phase III
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Anne Chiang, MD, PhD
- Benjamin Newton, MD
- Brooke Chaves
- Emily Collier, MD
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- Jade Vanacore
- James Vredenburgh, MD
- Jason Haldas, MD
- John Glendening
- Jose Morales-Marin
- Karishma Mehra, MBBS
- Kert Sabbath, MD, FACP
- Laura Sabourin
- Leena Rahmat
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Matthew Austin, MD
- Michael Grant, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Sharynn Hall, MD, PhD
- So Yeon Kim, MD
- Stacey LaRosa
- Stephen Lattanzi, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Vanna Dest
- Victor Chang, MD
- Vidya Kesavan
- Zia Rahman, MD
- Last Updated04/16/2024
- Study HIC#2000032970